Minerva Neurosciences Inc/$NERV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
- Ticker
- $NERV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7
- Headquarters
- Burlington, United States
- Website
- www.minervaneurosciences.com
NERV Metrics
BasicAdvanced
$124M
-
-$8.44
0.01
-
Price and volume
Market cap
$124M
Beta
0.01
52-week high
$8.80
52-week low
$1.96
Average daily volume
174K
Financial strength
Current ratio
33.02
Quick ratio
30.461
Long term debt to equity
-0.699
Total debt to equity
-0.699
Profitability
EBITDA (TTM)
-35.124
Management effectiveness
Return on assets (TTM)
-34.75%
Return on equity (TTM)
483.30%
Valuation
Price to book
-1.27
Price to tangible book (TTM)
-1.1
Price to free cash flow (TTM)
-2.993
Free cash flow yield (TTM)
-33.41%
Free cash flow per share (TTM)
-0.832
Growth
Earnings per share change (TTM)
355.47%
3-year earnings per share growth (CAGR)
21.90%
10-year earnings per share growth (CAGR)
0.16%
What the Analysts think about NERV
Analyst ratings (Buy, Hold, Sell) for Minerva Neurosciences Inc stock.
Analyst projections of the future price of Minerva Neurosciences Inc stock.
NERV Financial Performance
Revenues and expenses
NERV Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.